98%
921
2 minutes
20
Prophylactic and early thyroidectomy in germline mutation carriers allows the removal of the thyroid before medullary thyroid carcinoma (MTC) develops, or while it is still confined to the gland. This study was aimed to assess the clinicopathological features in carriers according to the age at surgery and the long-term outcomes after prophylactic and early thyroidectomy. A retrospective analysis of 63 operated asymptomatic carriers diagnosed after familial genetic screening was performed. Twenty-one carriers were operated at pediatric (<18 yrs) and 42 at adult (≥18 yrs) age. Serum preoperative calcitonin levels were significantly lower in pediatric compared to adult patients ( = 0.04); moreover, adult carriers had a greater frequency of microMTC at pathology ( = 0.009). Permanent postoperative morbidity occurred in 9.5% of patients, without differences between the two groups. Biochemical postoperative cure was achieved in all patients. At a median follow-up of 14 years, all C-cell hyperplasia patients are disease-free; conversely, biochemical, and structural recurrence of disease occurred in three adults and one pediatric patient with microMTC. The independent predictive factors of MTC were the age at surgery, the preoperative calcitonin level and the mutational risk profile ( < 0.02). In conclusion, prophylactic and early thyroidectomy are safe and effective procedures in achieving definitive cure in most carriers. However, since recurrences may occur at long-term in case of microMTC, thyroidectomy should be possibly performed earlier to prevent microMTC development.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776584 | PMC |
http://dx.doi.org/10.3390/cancers14246226 | DOI Listing |
J Dermatol
September 2025
Institute of Dermatology, Shanghai Children Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, China.
No consensus was made on whether all Nevus sebaceous (NS) should undergo prophylactic excision and the best age of surgery. This is a retrospective study. Patients who underwent surgery and were confirmed as NS by pathology during January 2014 to December 2023 in the Department of Dermatology of Xinhua hospital were included in this study.
View Article and Find Full Text PDFPhlebology
September 2025
Department of Orthopeadics, DongGuan Tungwah Hospital, DongGuan, China.
ObjectiveLower extremity varicose veins are a common chronic venous disorder, affecting approximately 23% of adults globally. Although endovenous thermal ablation, particularly radiofrequency ablation (RFA), has become the preferred treatment, post-procedural deep vein thrombosis (DVT) remains a concern. The necessity of pharmacologic prophylaxis following RFA remains controversial.
View Article and Find Full Text PDFCureus
August 2025
Haematology, Bon Secours Hospital, Cork, IRL.
Introduction: Venous thromboembolism (VTE), mainly deep vein thrombosis (DVT) and pulmonary embolism (PE), persists as a critical contributor to hospital-acquired mortality. Despite its largely preventable nature, early 2024 data from Bon Secours Hospital in Cork revealed alarmingly low compliance with VTE prophylaxis protocol.
Aim: This study evaluated the implementation efficacy of VTE risk assessment and prophylaxis in adult hospitalised patients at Bon Secours Hospital, Cork, according to National Institute for Health and Care Excellence (NICE) guidelines.
J Crohns Colitis
September 2025
Université de Paris, INSERM U1342, Institut de Recherche Saint-Louis, Paris, France.
Background And Aims: Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), remain heterogeneous disorders with variable response to biologics. Post-operative recurrence in CD is common despite surgery and prophylactic biotherapies. Understanding the inflammatory mediators associated with recurrence and treatment response could pave the way for personalized strategies.
View Article and Find Full Text PDFTransplant Direct
September 2025
Unidad Transplante de О́rganos, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain.
Extracorporeal photopheresis (ECP) is a well-established, safe, and effective immunomodulatory therapy currently used in clinics to decrease T cell-mediated immunity in various disorders, including autoimmune diseases and chronic rejection in organ transplantation. Although the ECP procedure has been shown to induce apoptotic cells that are reintroduced into the patient at the end of the treatment, the precise tolerogenic mechanisms mediated by ECP are not fully understood. Previous in vitro studies have demonstrated that early apoptotic cells express annexins on their cell surface, which suppress myeloid cell activation on stimulation with bacterial lipopolysaccharide through Toll-like receptors.
View Article and Find Full Text PDF